Article
Managed Health Care Associates, Inc, Announces Completion of Fifth Annual Independent Long Term Care Member Study
Managed Health Care Associates, Inc. (MHA), a leading health care service company focused on alternate site health care providers, announced the completion of its fifth annual Independent Long Term Care Member Study, the results of which were released at the 2012 MHA Business Summit, March 2, 2012 in Las Vegas, Nevada.
PRESS RELEASE
Managed Health Care Associates, Inc. (MHA), a leading health care service company focused on alternate site health care providers, announced the completion of its fifth annual Independent Long Term Care Member Study, the results of which were released at the 2012 MHA Business Summit, March 2, 2012, in Las Vegas, Nevada.
This study was first introduced in 2008 to provide MHA members and other industry stakeholders with additional insight into the operations of independent long term care pharmacies nationwide. Report findings represent participant data in demographic, financial and technology categories as well as by number of residents serviced and geographic region.
For the second consecutive year, the LTC member survey researched the growing utilization of specialty pharmaceuticals within LTC. In 2012, MHA expanded the study analysis by not only examining products dispensed but also reporting who was prescribing these specialized pharmaceuticals within the respective senior care setting. Study results continue to indicate strong growth in prescription product utilization of specialty medications used to treat multiple sclerosis (MS), inflammatory conditions and oral oncology over a comparative time period of 2010 vs. 2011.
Michelle Templin, MHA vice president of strategic business development, commented, "This year marks the fifth anniversary of the MHA Independent LTC Study. We are very proud to be the one organization capable of delivering this type of research report to our members and the market. The report has evolved over time with a steady increase in pharmacy participation and member feedback which has helped us refine data elements and expand the scope of the report to include the significant growth of specialty pharmaceutical utilization in the LTC setting. Our members value the report and we welcome the opportunity to make a meaningful contribution to support our members' business."
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa
